Sinovac shows promises. India searching for ways to store Pfizer’s.
The Chinese pharmaceutical giant, Sinovac Biotech has said that its vaccine for coronavirus, CoronaVac, has showed promising results among volunteers participating in its clinical trials being held in Brazil. Pfizer's vaccine seems to come with its own drawbacks to India as the Government is looking for ways to store the vaccine.
New Delhi, 18/11: The vaccine developed by the Chinese pharmaceutical company Sinovac Inc., CoronoaVac has shown to be triggering immune responses among volunteers in its clinical trials being held in Brazil, as per the reports. The claim for the vaccine came after western pharma moguls like Pfizer, Moderna Inc., and Russia’s Sputnik V have reported that their vaccines are more than 90% effective.
The vaccine developed by Sinovac Inc. has shown immune response and produced antibodies in the body of the clinical trial subjects, but the number is significantly lower than the ones produced by the body on its own in subjects who have recovered from the coronavirus. The researchers said that though the early-mid stage trials were not designed to test the efficacy of the vaccine, the results are enough to assess that it would provide enough protection from the coronavirus, as per the data obtained from their research in other vaccines and preclinical studies on macaques.
Indian authorities have said that the major problem that the country faces with the vaccine developed by Pfizer lies in its storage. The vaccine developed by Pfizer requires storage at very low temperatures. The authorities said that they were looking for ways to solve this logistics issue and provide people with the vaccine at the earliest, once it is approved.
